Jasper TherapeuticsJSPR
About: Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Employees: 64
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
88% more call options, than puts
Call options by funds: $179K | Put options by funds: $95K
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
17.53% less ownership
Funds ownership: 104.31% [Q4 2024] → 86.78% (-17.53%) [Q1 2025]
22% less funds holding
Funds holding: 86 [Q4 2024] → 67 (-19) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
59% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 29
83% less capital invested
Capital invested by funds: $334M [Q4 2024] → $56M (-$278M) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
BMO Capital Kostas Biliouris | 35%upside $4 | Market Perform Downgraded | 8 Jul 2025 |
JMP Securities Silvan Tuerkcan | 305%upside $12 | Market Outperform Maintained | 8 Jul 2025 |
Evercore ISI Group Gavin Clark-Gartner | 576%upside $20 | Outperform Maintained | 8 Jul 2025 |
HC Wainwright & Co. Emily Bodnar | 576%upside $20 | Buy Maintained | 7 Jul 2025 |
BTIG Justin Zelin | 576%upside $20 | Buy Maintained | 7 Jul 2025 |
Financial journalist opinion
Based on 12 articles about JSPR published over the past 30 days









